International Journal on Science and Technology

E-ISSN: 2229-7677   •   Impact Factor: 9.88

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 17 Issue 1 January-March 2026 Submit your research before last 3 days of March to publish your research paper in the issue of January-March.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 17 Issue 1
January-March 2026

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Application of CRISPR-Cas9 Technology in Visceral Leishmaniasis Research: Current Understanding and Future Perspective

Author(s) Mr. Suprativ Das, Dr. Abul Hasan Sardar
Country India
Abstract Visceral leishmaniasis (VL) is a severe disease that affects millions of people in the endemic areas due to Leishmania donovani parasites. There are no licensed vaccines, and chemotherapy is the mainstay to combat the disease. The clinical value of commonly used chemotherapeutic agents for the treatment of VL is now threatened due to the emergence of acquired drug resistance and toxicity. The CRISPR-Cas9 genome editing system have significantly advanced Leishmania research in terms of drug target validation and vaccine development. The CRISPR-Cas9 system is an adaptive immune system in bacteria, and it uses Cas9, an endonuclease guided by single-guide RNA (sgRNA) to introduce double-strand breaks at specific genomic loci. It is therefore more efficient for gene knockout, knock-in or base editing via HDR pathways, which makes it a better tool of gene editing than other currently available tools such as ZFNs and TALENs because of its flexibility, simplicity and scalability. To date, in Leishmania, CRISPR-Cas9 has helped in dissecting the drug resistance mechanisms, for example, RING-variant and transmembrane proteins in miltefosine resistance and the sterol 24 C methyltransferase (C24SMT) in amphotericin B resistance. It has also exposed new genes involving parasitic qualities that help it survive, multiply, and be virulent, and helped create new shapes of weakened strains for use in vaccines. Therefore, CRISPR-Cas9 proves to be an indispensable weapon in the assault on Leishmania biology and the development of VL treatment.
Keywords Visceral Leishmaniasis, CRISPR-Cas9, Leishmania donovani, Gene Editing, Drug Resistance
Field Biology > Genetics / Molecular
Published In Volume 17, Issue 1, January-March 2026
Published On 2026-02-04
View / Download PDF File

Share this


CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJSAT DOI prefix is
10.71097/IJSAT

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 16 Isu 3Cover Page Vol 16 Isu 2Cover Page Vol 16 Isu 1

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJSAT
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us Message on WhatsApp +91-9687-182-185 editor@ijsat.org